09606.HK
Duality Biotherapeutics, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 104.20
−4.75%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +123.0%
- EBITDA
- +52.8%
- EPS
- +46.9%
Three-year CAGR
- Revenue
- +940.8%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -51.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026